Skip to main content

Advertisement

SpringerLink
Log in

Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The purposes of this study were to determine the prevalence of metabolic syndrome (MetS) in patients with ankylosing spondylitis (AS) receiving anti-TNFα therapy and evaluate the association of the two conditions with clinical and laboratory findings and predictors of cardiovascular risk. In this cross-sectional study, 63 patients diagnosed with AS according to the modified New York criteria and treated with TNFα blockers and 33 healthy controls were submitted to clinical examination and anthropometric measurements. Glucose levels, lipid profile, and inflammatory markers were registered. The Framingham score (FS), atherogenic index of plasma (AIP), and waist-to-height ratio (WHtR) were calculated. MetS was diagnosed according to the revised National Cholesterol Education Program - Adult Treatment Panel III guidelines. The prevalence of MetS was higher among AS patients than controls (27 vs. 9.1%, p = 0.04). AS patients also had greater body mass index (27.6 kg/m2 ± 4.5 vs. 24.5 kg/m2 ± 2.7; p = 0.001) and WHtR (0.59 ± 0.08 vs. 0.49 ± 0.05; p < 0.01). Patients with MetS had higher FS (9.66 (4.08–20.5) vs. 2.54 (1.56–6.75); p < 0.001), WHtR (0.6444 ± 0.0706 vs. 0.5729 ± 0.0759; p = 0.001), and AIP (0.68 ± 0.46 vs. 0.34 ± 0.24; p = 0.02) than patients without MetS. When stratifying patients with and without MetS according to disease activity, the former had stronger predictors of cardiovascular risk than the latter, regardless of disease activity. MetS was more prevalent in AS patients than in controls. Predictors of cardiovascular risk were stronger in MetS patients than in non-MetS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gensler L (2011) Clinical features of ankylosing spondylitis. In: Hochberg MC (ed) Rheumatology, 3rd edn. Elsevier Ltd, Philadelphia, pp 1129–1133

    Chapter  Google Scholar 

  2. Coates LC, Marzo-Ortega H, Bennett AN, Emery P (2010) Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. Ther Adv Musculoskelet Dis 2:37–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pereira RM, de Carvalho JF, Bonfá E (2009) Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8:415–419

    Article  CAS  PubMed  Google Scholar 

  4. Tarantino G, Finelli C (2013) What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 19:3375–3384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ et al (2016) Network meta-analysis and cost per responder of tumor necrosis factor-α and interleukin inhibitors in the treatment of active ankylosing spondylitis. Rheumatol Ther 3:323–336

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668

    Article  CAS  PubMed  Google Scholar 

  7. Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES (2009) High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF alpha treatment: correlation with disease activity. Clin Exp Rheumatol 27:292–298

    CAS  PubMed  Google Scholar 

  8. Malesci D, Niglio A, Mennillo GA (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheum 26:710–714

    Article  Google Scholar 

  9. Kaur J (2014) A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014:943162

    PubMed  PubMed Central  Google Scholar 

  10. Dobiásová M, Frolich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34:583–588

    Article  PubMed  Google Scholar 

  11. Ashwell M, Lejeune S, Mcpherson K (1996) Ratio of waist circumference to height may be better indicator of need for weight management. BMJ 312:377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753

    Article  PubMed  Google Scholar 

  13. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  PubMed  Google Scholar 

  14. Savva SC, Lamnisos D, Kafatos AG (2013) Predicting cardiometabolic risk: waist-to-height ratio or BMI: a meta-analysis. Diabetes Metab Syndr Obes 3:403–419

    Article  Google Scholar 

  15. Dobiásová M (2006) AIP—atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 52:64–71

    PubMed  Google Scholar 

  16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    CAS  PubMed  Google Scholar 

  17. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS: a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818

    Article  PubMed  Google Scholar 

  18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752

    Article  PubMed  Google Scholar 

  19. Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH (2014) Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int 34:265–270

    Article  CAS  PubMed  Google Scholar 

  20. Ashwell M, Gunn P, Gibson S (2012) Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 13:275–286

    Article  CAS  PubMed  Google Scholar 

  21. Browning LM, Hsieh SD, Ashwell M (2010) A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev 23:247–269

    Article  PubMed  Google Scholar 

  22. Dominguez LJ, Barbagallo M (2016) The biology of metabolic syndrome and aging. Curr Opin Clin Nutr Metab Care 19:5–11

    Article  CAS  PubMed  Google Scholar 

  23. Lee YH, Pratley RE (2005) The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 5:70–75

    Article  CAS  PubMed  Google Scholar 

  24. Onat A, Can G, Kaya H, Hergenç G (2010) “Atherogenic index of plasma” (log 10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 4:89–98

    Article  PubMed  Google Scholar 

  25. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Post-graduate Program in Medical Sciences/Medical School, University of Fortaleza (Unifor), Fortaleza, Brazil

    Diego Germano Maia, Kristopherson Lustosa Augusto & Carlos Ewerton Maia Rodrigues

  2. Rheumatology Division, Walter Cantídio University Hospital, Federal University of Ceará, Fortaleza, Brazil

    Mailze Campos Bezerra

Authors
  1. Diego Germano Maia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristopherson Lustosa Augusto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mailze Campos Bezerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Ewerton Maia Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diego Germano Maia.

Ethics declarations

The study was approved by the Hospital Geral de Fortaleza’s research ethics committee and filed under entry #880.336. All participants gave their informed written consent and the study was performed in accordance with the 1964 Declaration of Helsinki.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maia, D.G., Augusto, K.L., Bezerra, M.C. et al. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol 36, 2371–2376 (2017). https://doi.org/10.1007/s10067-017-3623-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3623-8

Keywords

Search

Navigation